|
|
局部进展期胃癌的治疗策略：手术前新辅助化疗的发展与进展
|
Abstract:
胃癌是全球范围内最常见的恶性肿瘤之一，而局部进展期胃癌是指肿瘤已经累及胃壁深层或局部周围组织，但尚未出现远处转移的阶段。这种阶段的胃癌治疗具有挑战性，需要综合性的多学科治疗策略。近年来，手术前新辅助化疗作为一种新兴的治疗策略，备受关注并成为局部进展期胃癌治疗的研究热点。本综述旨在探讨手术前新辅助化疗在局部进展期胃癌治疗中的发展与进展，并为患者的治疗决策提供更为科学有效的依据。
Gastric cancer is one of the most common malignant tumors worldwide. Locally advanced gastric cancer refers to a disease stage in which the tumor has been involved in the deep gastric wall or local surrounding tissues, but no distant metastasis has occurred. Treatment of this stage of gastric cancer is challenging and requires an integrated multidisciplinary treatment strategy. In recent years, as a new treatment strategy, neoadjuvant chemotherapy before surgery has attracted much attention and become a research hotspot in the treatment of locally advanced gastric cancer. This review aims to explore the development and progress of preoperative neoadjuvant chemotherapy in the treatment of locally advanced gastric cancer, in order to provide a more scientific and effective basis for patients’ treatment decisions.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386. https://doi.org/10.1002/ijc.29210 |
| [3] | 陈佳鑫, 隋红. 局部进展期胃癌围手术期治疗研究进展[J]. 现代肿瘤医学, 2023, 31(4): 784-788. |
| [4] | Li, G.Z., Doherty, G.M. and Wang, J. (2022) Surgical Management of Gastric Cancer: A Review. JAMA Surgery, 157, 446-454. https://doi.org/10.1001/jamasurg.2022.0182 |
| [5] | 顾梦会, 袁政. 新辅助治疗后接受胃癌根治术患者术后并发症及预后影响因素分析[J]. 吉林医学, 2023, 44(6): 1482-1485. |
| [6] | 刘壮. 胃癌根治术 新辅助化疗治疗进展期胃癌的临床效果分析[J]. 中国现代药物应用, 2023, 17(22): 112-114. |
| [7] | Wilke, H., Preusser, P., Fink, U., et al. (1989) Preoperative Chemotherapy in Locally Advanced and Nonresectable Gastric Cancer: A Phase II Study with Etoposide, Doxorubicin, and Cisplatin. Journal of Clinical Oncology, 7, 1318-1326. https://doi.org/10.1200/JCO.1989.7.9.1318 |
| [8] | Tokunaga, M., Sato, Y., Nakagawa, M., et al. (2020) Perioperative Chemotherapy for Locally Advanced Gastric Cancer in Japan: Current and Future Perspectives. Surgery Today, 50, 30-37. https://doi.org/10.1007/s00595-019-01896-5 |
| [9] | Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. https://doi.org/10.3322/caac.21657 |
| [10] | Wang, Z., Shao, C., Wang, Y., et al. (2022) Efficacy and Safety of Neoadjuvant Immunotherapy in Surgically Resectable Esophageal Cancer: A Systematic Review and Meta-Analysis. International Journal of Surgery, 104, Article 106767. https://doi.org/10.1016/j.ijsu.2022.106767 |
| [11] | Oronsky, B., Reid, T., Larson, C., et al. (2020) Locally Advanced Rectal Cancer: The Past, Present, and Future. Seminars in Oncology, 47, 85-92. https://doi.org/10.1053/j.seminoncol.2020.02.001 |
| [12] | Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2018) Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy in Early Breast Cancer: Meta-Analysis of Individual Patient Data from Ten Randomised Trials. The Lancet Oncology, 19, 27-39. https://doi.org/10.1016/S1470-2045(17)30777-5 |
| [13] | Wang, F.H., Zhang, X.T., Li, Y.F., et al. (2021) The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer, 2021. Cancer Communications, 41, 747-795. https://doi.org/10.1002/cac2.12193 |
| [14] | 蒋祈, 张鹏, 陶凯雄. 美国国立综合癌症网络临床实践指南: 胃癌(2022.V2)更新解读[J]. 临床外科杂志, 2023, 31(1): 21-23. |
| [15] | 梁寒. 局部进展期/Ⅳ期胃或食管胃结合部腺癌新辅助及转化治疗进展[J]. 腹部外科, 2023, 36(2): 79-82, 87. |
| [16] | Lin, W.L., Li, D.G., Chen, Q., et al. (2004) Clinical and Experimental Study of Oxaliplatin in Treating Human Gastric Carcinoma. World Journal of Gastroenterology, 10, 2911-2915. https://doi.org/10.3748/wjg.v10.i19.2911 |
| [17] | 何家赓, 袁明, 木拉提, 等. 替吉奥胶囊联合奥沙利铂注射液治疗进展期胃癌的临床效果观察[J]. 临床合理用药杂志, 2019, 12(29): 51-52. |
| [18] | 丁德权, 曹齐生, 陈媛媛, 等. 胃癌根治术联合SOX方案辅助化疗治疗进展期胃癌的疗效与安全性[J]. 中国普通外科杂志, 2021, 30(10): 1245-1250. |
| [19] | 郑钧尹, 夏浩沄, 陈鸿源. 奥沙利铂联合替吉奥新辅助化疗在胃癌根治术患者中的应用效果[J]. 中国医学创新, 2022, 19(28): 1-5. |
| [20] | 曾德强, 王亮, 梁志平, 等. 替吉奥联合奥沙利铂新辅助化疗方案治疗局部进展期胃癌患者的疗效分析[J]. 现代诊断与治疗, 2022, 33(8): 1136-1138. |
| [21] | Ilson, D.H. (2019) Advances in the Treatment of Gastric Cancer: 2019. Current Opinion in Gastroenterology, 35, 551-554. https://doi.org/10.1097/MOG.0000000000000577 |
| [22] | Wang, X., Li, S., Sun, Y., et al. (2021) The Protocol of a Prospective, Multicenter, Randomized, Controlled Phase III Study Evaluating Different Cycles of Oxaliplatin Combined with S-1 (SOX) as Neoadjuvant Chemotherapy for Patients with Locally Advanced Gastric Cancer: RESONANCE-II Trial. BMC Cancer, 21, Article No. 20. https://doi.org/10.1186/s12885-020-07764-7 |
| [23] | 谢兴江, 彭强, 侯松林, 等. SOX和XELOX在进展期胃癌新辅助化疗中疗效及不良反应差异的Meta分析[J]. 医学信息, 2021, 34(7): 67-73. |
| [24] | 应晨辉. XELOX方案新辅助化疗联合腹腔镜胃癌根治术治疗进展期胃癌患者的效果[J]. 中国民康医学, 2023, 35(12): 69-71. |
| [25] | 杜晓辉, 晏阳, 刘帛岩. 2022版中国临床肿瘤学会胃癌诊疗指南更新解读[J]. 临床外科杂志, 2022, 30(9): 805-808. |
| [26] | 张喆, 陈萍. 白蛋白结合型紫杉醇联合替吉奥方案在胃癌术前新辅助化疗中的疗效分析[J]. 慢性病学杂志, 2021, 22(12): 1789-1794. |
| [27] | 周志峰, 叶炆凤. 奥沙利铂、卡培他滨联合紫杉醇脂质体新辅助化疗治疗进展期胃癌的临床效果[J]. 临床合理用药杂志, 2022, 15(23): 69-72. |
| [28] | Ma, J., Xiao, M., Li, X., et al. (2022) Analysis of the Efficacy and Safety of Paclitaxel (Albumin-Bound) Combined with S-1 and Oxaliplatin Combined with S-1 in the First-Line Treatment of Advanced Gastric Cancer: A Cohort Study. Journal of Gastrointestinal Oncology, 13, 630-636. https://doi.org/10.21037/jgo-22-279 |
| [29] | 成新平. 白蛋白结合型紫杉醇联合SOX方案在局部进展期胃癌新辅助化疗中的近期疗效及安全性研究[D]: [硕士学位论文]. 兰州: 甘肃中医药大学, 2023. |
| [30] | Li, K., Zhang, A., Li, X., et al. (2021) Advances in Clinical Immunotherapy for Gastric Cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1876, Article 188615. https://doi.org/10.1016/j.bbcan.2021.188615 |
| [31] | Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., et al. (2012) Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2. Journal of Experimental Medicine, 209, 1201-1217. https://doi.org/10.1084/jem.20112741 |
| [32] | Yu, Y., Ma, X., Zhang, Y., et al. (2019) Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. Journal of Cancer, 10, 2754-2763. https://doi.org/10.7150/jca.31755 |
| [33] | Yost, K.E., Satpathy, A.T., Wells, D.K., et al. (2019) Clonal Replacement of Tumor-Specific T Cells Following PD-1 Blockade. Nature Medicine, 25, 1251-1259. https://doi.org/10.1038/s41591-019-0522-3 |
| [34] | Xu, J., Jiang, H., Pan, Y., et al. (2021) LBA53 Sintilimab Plus Chemotherapy (Chemo) versus Chemo as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (ORIENT-16): First Results of a Randomized, Double-Blind, Phase III Study. Annals of Oncology, 32, S1331. https://doi.org/10.1016/j.annonc.2021.08.2133 |
| [35] | Guo, H., Ding, P., Sun, C., et al. (2022) Efficacy and Safety of Sintilimab Plus XELOX as a Neoadjuvant Regimen in Patients with Locally Advanced Gastric Cancer: A Single-Arm, Open-Label, Phase II Trial. Frontiers in Oncology, 12, Article 927781. https://doi.org/10.3389/fonc.2022.927781 |
| [36] | 焦福智. 免疫联合化疗在局部进展期胃癌新辅助治疗中的疗效及安全性研究[D]: [硕士学位论文]. 兰州: 兰州大学, 2023. |
| [37] | 徐攀攀. 信迪利珠单抗结合FOLFOX6化疗方案治疗进展期胃癌患者疗效分析[J]. 华北理工大学学报(医学版), 2023, 25(6): 443-448. |
| [38] | Jiang, H., Yu, X., Li, N., et al. (2022) Efficacy and Safety of Neoadjuvant Sintilimab, Oxaliplatin and Capecitabine in Patients with Locally Advanced, Resectable Gastric or Gastroesophageal Junction Adenocarcinoma: Early Results of a Phase 2 Study. Journal for ImmunoTherapy of Cancer, 10, e003635. https://doi.org/10.1136/jitc-2021-003635 |
| [39] | Tang, Z., Wang, Y., Liu, D., et al. (2021) 1385P Phase II Study of Neoadjuvant Camrelizumab Combined with Chemoradiation for Locally Advanced Proximal Gastric Cancer (Neo-PLANET, NCT03631615). Annals of Oncology, 32, S1049. https://doi.org/10.1016/j.annonc.2021.08.1494 |
| [40] | 刘真, 雷雨虹. 卡瑞利珠单抗联合mFOLFOX6方案治疗进展期胃癌的近远期疗效[J]. 西藏医药, 2022, 43(6): 67-69. |
| [41] | 赵福坤, 董鹤翔, 朱祥, 等. CT对于进展期胃癌新辅助化疗疗效的预测价值[J]. 中国普外基础与临床杂志, 2023, 30(6): 715-720. |
| [42] | Giganti, F., Orsenigo, E., Arcidiacono, P.G., et al. (2016) Preoperative Locoregional Staging of Gastric Cancer: Is There a Place for Magnetic Resonance Imaging? Prospective Comparison with EUS and Multidetector Computed Tomography. Gastric Cancer, 19, 216-225. https://doi.org/10.1007/s10120-015-0468-1 |
| [43] | Yoshida, S., Tanaka, S., Kunihiro, K., et al. (2005) Diagnostic Ability of High-Frequency Ultrasound Probe Sonography in Staging Early Gastric Cancer, Especially for Submucosal Invasion. Abdominal Imaging, 30, 518-523. https://doi.org/10.1007/s00261-004-0287-z |
| [44] | 杨梓怡, 顾丙新, 许晓平, 等. 18F-FDG和68Ga-FAPI PET/CT在不同恶性肿瘤肺转移诊断中的对比研究[J]. 中国癌症杂志, 2023, 33(9): 829-833. |
| [45] | 佟依霖. 评价及比较Mandard和Becker肿瘤退缩分级在局部进展期胃腺癌患者中的预测价值[D]: [硕士学位论文]. 沈阳: 中国医科大学, 2021. |
| [46] | Karamitopoulou, E., Thies, S., Zlobec, I., et al. (2014) Assessment of Tumor Regression of Esophageal Adenocarcinomas after Neoadjuvant Chemotherapy: Comparison of 2 Commonly Used Scoring Approaches. The American Journal of Surgical Pathology, 38, 1551-1556. https://doi.org/10.1097/PAS.0000000000000255 |
